|
5-year patient-reported outcomes of bowel and urinary bother in the CHHiP trial (CRUK/06/016). |
|
|
Honoraria - Janssen; Sandoz; Takeda |
Consulting or Advisory Role - Cadence Research and Consulting; FirstWord; Janssen; Janssen Research & Development; Sandoz; Takeda |
Speakers' Bureau - Janssen; Janssen-Cilag |
Patents, Royalties, Other Intellectual Property - Abiraterone acetate was developed at The Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. Professor Dearnaley is on the Institute’s Rewards to Inventors list for abiraterone acetate. (Inst) |
Expert Testimony - Vitality Life |
Travel, Accommodations, Expenses - Janssen; Takeda |
|
|
Research Funding - Accuray (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Oncology; Bayer; Ipsen; Janssen; Tolmar |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; BN ImmunoTherapeutics; Janssen |
Consulting or Advisory Role - Bayer Schering Pharma; BN ImmunoTherapeutics; Janssen |
Research Funding - Bayer Schering Pharma (Inst) |
Travel, Accommodations, Expenses - Bayer Schering Pharma; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Janssen-Cilag |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Merck Serono (I) |
|
|
Research Funding - Accuray (Inst); AstraZeneca (Inst); Aventis Pharma (Inst); Bayer (Inst) |